Hualan Biological Vaccine Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Hualan Biological Vaccine is forecast to grow earnings and revenue by 33.3% and 28% per annum respectively. EPS is expected to grow by 33.2% per annum. Return on equity is forecast to be 14.6% in 3 years.
Anahtar bilgiler
33.3%
Kazanç büyüme oranı
33.2%
EPS büyüme oranı
Biotechs kazanç büyümesi | 44.8% |
Gelir büyüme oranı | 28.0% |
Gelecekteki özkaynak getirisi | 14.6% |
Analist kapsamı | Low |
Son güncelleme | 18 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly
Oct 08Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk
Jul 25Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's
Jun 11Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)
Apr 03Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next
Apr 02Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity
Apr 01An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued
Mar 04Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 3,657 | 1,344 | N/A | 1,209 | 3 |
12/31/2025 | 3,116 | 1,114 | N/A | 1,061 | 4 |
12/31/2024 | 2,644 | 929 | N/A | 1,113 | 4 |
9/30/2024 | 1,650 | 498 | 695 | 750 | N/A |
6/30/2024 | 2,296 | 777 | 688 | 749 | N/A |
3/31/2024 | 2,300 | 805 | 724 | 792 | N/A |
12/31/2023 | 2,410 | 860 | 825 | 888 | N/A |
9/30/2023 | 1,984 | 645 | 752 | 813 | N/A |
6/30/2023 | 915 | 330 | 667 | 732 | N/A |
3/31/2023 | 1,956 | 614 | 459 | 533 | N/A |
1/1/2023 | 1,826 | 520 | 196 | 289 | N/A |
9/30/2022 | 1,997 | 598 | -162 | 233 | N/A |
6/30/2022 | 2,879 | 948 | -254 | 184 | N/A |
3/31/2022 | 1,833 | 624 | -216 | 274 | N/A |
1/1/2022 | 1,830 | 621 | -67 | 569 | N/A |
9/30/2021 | 2,608 | 1,004 | 124 | 608 | N/A |
6/30/2021 | 2,441 | 922 | 360 | 946 | N/A |
3/31/2021 | 2,439 | 934 | 285 | 897 | N/A |
12/31/2020 | 2,426 | 925 | 161 | 694 | N/A |
12/31/2019 | 1,049 | 375 | 131 | 275 | N/A |
12/31/2018 | 803 | 270 | 32 | 94 | N/A |
12/31/2017 | 285 | -77 | N/A | 22 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 301207's forecast earnings growth (33.3% per year) is above the savings rate (2.9%).
Kazançlar ve Piyasa: 301207's earnings (33.3% per year) are forecast to grow faster than the CN market (25.8% per year).
Yüksek Büyüme Kazançları: 301207's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: 301207's revenue (28% per year) is forecast to grow faster than the CN market (14% per year).
Yüksek Büyüme Geliri: 301207's revenue (28% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 301207's Return on Equity is forecast to be low in 3 years time (14.6%).